Insulin Peglispro
drugOn this page
Also known as Insulina peglisproInsuline peglisproLY-2605541LY2605541
Summary
Insulin Peglispro (CHEMBL2108569) is a phase-3 clinical-stage protein; indicated across 2 conditions including type 1 diabetes mellitus and type 2 diabetes mellitus.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Protein
- Indications: 2 conditions
- Clinical trials: 25
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2108569 |
| Name | Insulin Peglispro |
| Type | Protein |
| Max phase | 3 |
Also known as: Insulin peglispro, Insulina peglispro, Insuline peglispro, LY-2605541, LY2605541, INSULIN PEGLISPRO
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| type 1 diabetes mellitus | 3 | MONDO:0005147 | MONDO:0005147 |
| type 2 diabetes mellitus | 3 | MONDO:0005148 | MONDO:0005148 |
Clinical trials
Total trials: 25.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE1 | 13 |
| PHASE3 | 10 |
| PHASE2 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01435616 | PHASE3 | COMPLETED | A Study in Patients With Type 2 Diabetes Mellitus |
| NCT01454284 | PHASE3 | COMPLETED | A Study in Participants With Type I Diabetes Mellitus |
| NCT01468987 | PHASE3 | COMPLETED | A Study in Participants With Type 2 Diabetes Mellitus |
| NCT01481779 | PHASE3 | COMPLETED | A Study in Participants With Type 1 Diabetes Mellitus |
| NCT01582451 | PHASE3 | COMPLETED | A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus |
| NCT01790438 | PHASE3 | COMPLETED | A Study to Compare a New Long-Acting Insulin (LY2605541) and Human Insulin NPH in Participants With Type 2 Diabetes |
| NCT01792284 | PHASE3 | COMPLETED | A Study of LY2605541 in Participants With Type 1 Diabetes Mellitus |
| NCT01894568 | PHASE3 | COMPLETED | A Study Comparing Insulin Peglispro With Insulin Glargine as Basal Insulin Treatment |
| NCT02106364 | PHASE3 | WITHDRAWN | A Study of Insulin Peglispro (LY2605541) in Participants With Type 2 Diabetes Mellitus |
| NCT02132637 | PHASE3 | COMPLETED | A Study to Compare the Effect of a Double Dose of Two Long-acting Insulin Therapies in Participants With Type 2 Diabetes |
| NCT01027871 | PHASE2 | COMPLETED | A Study for Patients With Type 2 Diabetes |
| NCT01049412 | PHASE2 | COMPLETED | A Study for Patients With Type 1 Diabetes |
| NCT01654380 | PHASE1 | COMPLETED | A Study of LY2605541 Versus Insulin Glargine on Blood Sugar |
| NCT01751399 | PHASE1 | COMPLETED | A Single Dose Study of LY2605541 in Participants With Liver Impairment |
| NCT01769404 | PHASE1 | COMPLETED | A Study of LY2605541 and Glargine in Participants With Type 1 Diabetes |
| NCT01771250 | PHASE1 | COMPLETED | A Study of Insulin Peglispro and Glargine on Fats in Participants With Type 1 Diabetes |
| NCT01784211 | PHASE1 | COMPLETED | A Study of LY2605541 and Glargine and Exercise in Participants With Type 1 Diabetes |
| NCT01818245 | PHASE1 | COMPLETED | A Study of LY2605541 in Healthy Participants and in the Elderly |
| NCT01871493 | PHASE1 | COMPLETED | A Study of LY2605541 and Insulin Lispro Mixture in Healthy Participants |
| NCT01877265 | PHASE1 | COMPLETED | A Study of LY2605541 in Healthy Participants |
| NCT01925989 | PHASE1 | COMPLETED | A Study of How Insulin Peglispro (LY2605541) and Insulin Glargine Affect the Breakdown of Fat and Sugar in Type 1 Diabetics |
| NCT01995526 | PHASE1 | COMPLETED | A Study of Insulin Peglispro in Healthy Male Japanese Participants |
| NCT02109029 | PHASE1 | COMPLETED | A Study of LY2605541 (Insulin Peglispro) and Human Insulin Concentrations in Fat Tissue |
| NCT02152384 | PHASE1 | COMPLETED | A Study to Compare and Measure the Effects of Insulin Peglispro (LY2605541) and Glargine on Meal Time Insulin Requirements |
| NCT02197520 | PHASE1 | COMPLETED | A Study To Compare the Effects of Insulin Peglispro and Glargine on Insulin Sensitivity and Meal Time Insulin Requirements in Type 2 Diabetics |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: type 1 diabetes mellitus, type 2 diabetes mellitus